This analysis is based on closing-price data as of November 20, 2026. Whether you're researching Sonic Healthcare (SHL) on the ASX or learning how to read stock charts, here are objective support, resistance and technical invalidation levels built from the RSI, MACD and ATR indicators.
Sonic Healthcare closed at $21.65 on November 20, 10.8% below its $24.27 52-week high and 19.5% above its $18.11 52-week low. The two-year chart is still a downtrend from the August 2025 gap near $28, but the last month has turned: the close has held above SMA20 since Oct 20 and above SMA60 since Nov 5, SMA5 > SMA20 > SMA60 has been in place since Nov 12, and the 20-day high was broken repeatedly from Nov 5 onward. The largest single gain — +6.28% on Nov 19 — came on the day the company was reported to have reaffirmed its full-year earnings guidance at its AGM, so this page treats the last two sessions as event-assisted and weighs the structure that formed before them separately. RSI at 81.3 and a close above the upper Bollinger Band show how stretched the move now is.
| Item | Value | Reading |
|---|---|---|
| Close | $21.65 | −10.8% from 52w high · +19.5% from 52w low; a new 20-day closing high |
| 52-week range | $18.11 – $24.27 | High set intraday on Feb 19, 2026; low set intraday on Oct 12, 2026 |
| SMA 5 / 20 / 60 | $20.62 / $19.83 / $19.27 | Close > SMA5 > SMA20 > SMA60; the 5-20-60 ordering has held since Nov 12 |
| Bollinger (20) | $21.19 / $19.83 / $18.46 | Band width 13.76%; the close is above the upper band — stretched, not a quiet breakout |
| aVWAP (2y anchor Aug 21, 2025) | $20.97 | Price 3.3% above the average anchored to the August 2025 gap-down |
| aVWAP (90d anchor Aug 31, 2026) | $19.41 | Price 11.5% above the average anchored to the Aug 31 heavy-volume session |
| RSI(14) | 81.3 | Overbought (81.29 on 90d, 81.26 on 2y); bullish RSI divergence flagged before the advance |
| Mansfield RS (vs the S&P/ASX 200) | +6.5% | Outperform, rising; +14.17 points on the week, +16.41 on the month — crossed above zero this week |
| MACD (12,26,9) | 0.4672 / 0.2892 / +0.1780 | Above signal since the Sep 16 golden cross and above zero (two-year frame 0.4680 / 0.2903 / +0.1777) |
| ADX(14) | 30.6 | Strong-trend reading (30.2 on the two-year frame) |
| ATR(14) | $0.42 (1.96%) | 2×ATR spans about 3.9% of the share price |
| OBV (2y / 90d) | early accumulation / early accumulation | Above MA20 but flat on both frames; no OBV divergence flagged; OBV-to-MA20 gap +11.83% / +16.57% |
| Volume vs 20d avg | 1.721× | 2,763,790 shares against a 1,605,536 average on Nov 20 |
| 1×ATR / 2×ATR technical invalidation | $21.23 / $20.80 | Volatility-based structural reference levels below the close (two-year frame $21.23 / $20.80) |
SHL_price-90d-2026-11-22.svgOn the two-year chart the defining event is the August 2025 gap down from the $28 area, which left an unfilled gap from $28.00 to $28.69 overhead and anchors the two-year aVWAP ($20.97). Since then price has moved in a series of lower swings: a spike to the $24.27 52-week high on Feb 19, 2026 (+9.9% that session), a slide into mid-year, a rally to $23.56 on Aug 19, then an Aug 20 fall of −9.25% and a drift down to the $18.11 intraday low on Oct 12. The current close is back above the two-year aVWAP, which price lost after the Aug 20, 2026 drop.
The 90-day structure shows the turn forming in stages. The close moved above SMA20 on Oct 20 and above SMA60 on Nov 5, and the 20-day closing high was broken on Nov 5, Nov 6 and Nov 17 (+0.45%) — all before the AGM. SMA5 > SMA20 > SMA60 has held since Nov 12 (earlier runs began Jun 24 and Jul 29 and ended on Aug 24). On Nov 19 the shares rose +6.28% to $21.33, the day Sonic was reported to have reaffirmed its full-year earnings guidance at its AGM (a single-source report); healthcare was one of the stronger sectors that session while the broad market fell. Nov 20 added +1.50% to $21.65 — the session that produced this week's breakout reading. Because the pre-AGM 20-day-high breaks were small and the AGM day supplied most of the distance, the breakout is better read as an existing base being lifted by an event than as a clean technical break on its own.
The two-year Fibonacci swing in the data runs from $23.56 (Aug 19) down to $18.73 (Sep 2). Its 61.8% retracement at $21.71 sits just above the close, and 78.6% is $22.53. The 23.6% ($19.87), 38.2% ($20.58) and 50% ($21.14) levels are labelled resistance in the data, but price now trades above all three, so they describe levels already reclaimed rather than overhead supply. The 90-day swing runs from $18.87 (Oct 28) to $21.65 (Nov 20): the 23.6% retracement is $20.99, 38.2% $20.59, 50% $20.26 and 61.8% $19.93, all labelled support.
SHL_volume-90d-2026-11-22.svgThe Aug 31 bar dominates the panel: 53,716,123 shares on a close of $19.59, roughly ten times the normal daily turnover, with no cause identified in the data. It anchors the 90-day aVWAP and inflated the 20-day average for most of September. Through October and early November volume mostly ran near or below average.
In the final week, Nov 17 traded 2,221,212 shares on the +0.45% pre-AGM 20-day-high break, Nov 19 traded 2,547,565 shares on the +6.28% AGM session, and Nov 20 traded 2,763,790 shares — 1.721× its 20-day average — on the +1.50% follow-through. These are above-average sessions, but none is near the 3× level that typically marks an event-driven spike. The screened ASX universe's median volume ratio ran about 0.71–1.06× from Nov 16 to Nov 20, a normal range, so the readings are specific to this stock rather than a market-wide distortion.
SHL_macd-90d-2026-11-22.svgThe MACD line is 0.4672 against a signal of 0.2892, a histogram of +0.1780. The golden cross came on Sep 16 from deep below zero, after the late-August decline, and the line has climbed steadily since, crossing above zero in early November. The last two sessions steepened the line and widened the histogram again after a brief narrowing in mid-November. Momentum is positive and expanding; a narrowing histogram over the coming sessions would be the first sign that the AGM-driven push is fading.
SHL_rsi-90d-2026-11-22.svgRSI(14) is 81.3, well inside the overbought zone. A bullish RSI divergence is flagged on both frames: price made a lower closing low from $19.00 (Sep 11) to $18.87 (Oct 28), while RSI made a higher low, from 31.92 to 47.09 on the 90-day frame (33.19 to 47.25 on the two-year frame). That divergence has since been followed by the advance it hinted at. The current reading is a different matter — RSI above 80 after a two-day jump shows a stretched short-term condition, which often leads to a pause or pullback even within an intact uptrend. It is a caution about timing, not a reversal signal.
SHL_rs-90d-2026-11-22.svgMansfield RS vs the S&P/ASX 200 is +6.5%, above zero (outperform), with a rising slope. A week ago it was −7.62, so the week added 14.17 points; a month ago it was −9.87, a gain of 16.41 points — positive-accelerating on both views. The two-year panel shows RS below zero for nearly all of the period since August 2025, with a brief excursion above zero in mid-August 2026 that reversed with the Aug 20 drop. Most of this week's gain came in the last two sessions, when the stock rose while the broad market fell, so the reading is new and not yet tested by a market rebound.
SHL_atr_adx-90d-2026-11-22.svgATR(14) is $0.42, or 1.96% of price, which sets the 1×ATR reference at $21.23 and the 2×ATR technical invalidation level at $20.80, 3.9% below the close. ATR had contracted to the lowest levels of the 90-day window in mid-November — a quiet base — and turned up sharply with the AGM session. ADX is 30.6 (30.2 on the two-year frame), above the 25 line that marks a strong trend and turning higher. ADX measures strength, not direction; with the moving averages ordered upward it describes a firming short-term advance, but one that has only just emerged from a low-volatility range.
SHL_obv-90d-2026-11-22.svgOBV is tagged early accumulation on both frames — above its MA20 but with a flat slope. No OBV divergence is flagged on either frame. The OBV-to-MA20 gap is +11.83% on the two-year frame and +16.57% on the 90-day frame; these measure distance from the moving average, not divergence.
Context: OBV adds or subtracts a session's full volume by the sign of the close, so the Aug 31 bar — 53.7 million shares on a down close — cut OBV in a single step, the cliff visible on both panels. OBV's deeply negative level traces largely to that one session, which limits how much the absolute level says about recent participation. Since late October OBV has edged higher, and the last three sessions lifted it further, but the improvement is gradual rather than a decisive turn.
| Scenario | Probability | Path | Trigger / Invalidation |
|---|---|---|---|
| Breakout extends | 30% | Price clears the two-year Fibonacci 61.8% level ($21.71) and works toward the 78.6% level ($22.53), with Mansfield RS holding above zero | Trigger: a daily close above $21.71 on above-average volume. Invalidation: a close back below $20.80 |
| Pause and retest | 45% | RSI unwinds from overbought as price consolidates or pulls back toward the $20.97–$20.99 zone (two-year aVWAP and 90-day 23.6% retracement) | Trigger: closes holding between $20.80 and $21.71. The structure remains intact while closes stay above the $20.80 2×ATR level |
| Event move fades | 25% | The AGM gain is given back: price slips below $20.80 toward the 38.2%–50% retracements ($20.59–$20.26) and SMA20 ($19.83) | Trigger: a daily close below $20.80 (2×ATR technical invalidation) |
| Level | Role | Distance | Basis |
|---|---|---|---|
| $22.53 | Resistance | +4.1% | Two-year Fibonacci 78.6% retracement of the Aug 19 → Sep 2 swing |
| $21.71 | Resistance | +0.3% | Two-year Fibonacci 61.8% retracement; Nov 20 intraday high $21.68 just below |
| $21.65 | Current | — | Nov 20, 2026 close (0% of the 90-day Fibonacci swing) |
| $21.14 | Reclaimed level | −2.3% | Two-year Fibonacci 50% (labelled resistance in the data, now below price); upper Bollinger Band $21.19 and 1×ATR $21.23 alongside |
| $20.99 | Support | −3.0% | 90-day Fibonacci 23.6% retracement; two-year aVWAP $20.97 alongside |
| $20.80 | Invalidation | −3.9% | 2×ATR technical invalidation level |
| $20.59 | Support | −4.9% | 90-day Fibonacci 38.2% retracement; two-year 38.2% level $20.58 alongside |